

Title	Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy
Authors	Fernandez-Rivas, Montserrat;Vereda, Andrea;Vickery, Brian P.;Sharma, Vibha;Nilsson, Caroline;Muraro, Antonella;Hourihane, Jonathan O'B.;DunnGalvin, Audrey;du Toit, George;Blumchen, Katharina;Beyer, Kirsten;Smith, Alex;Ryan, Robert;Adelman, Daniel C.;Jones, Stacie M.
Publication date	2021-07-28
Original Citation	Fernandez-Rivas, M., Vereda, A., Vickery, B. P., Sharma, V., Nilsson, C., Muraro, A., Hourihane, J. O'B., DunnGalvin, A., du Toit, G., Blumchen, K., Beyer, K., Smith, A., Ryan, R., Adelman, D. C. and Jones, S. M. (2021) 'Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy', <i>Allergy</i> , 77(3), pp. 991-1003. doi: 10.1111/all.15027
Type of publication	Article (peer-reviewed)
Link to publisher's version	10.1111/all.15027
Rights	© 2021, Aimmune Therapeutics. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. - https://creativecommons.org/licenses/by-nc/4.0/
Download date	2025-08-03 16:33:01
Item downloaded from	https://hdl.handle.net/10468/13622



University College Cork, Ireland
Coláiste na hOllscoile Corcaigh

**PALISADE participants aged 4–17 years who
completed PTAH treatment
(N=294)**

**Elected to receive extended
treatment in ARC004
(N=256)**

Group A
300 mg once daily x 28 weeks
(n=112)

Group B
300 mg once daily x 56 weeks
(n=31)

Cohort 3b
n=31

Cohort 3c
n=34

Cohort 2
n=48

Withdrew before
treatment 3

Discontinued 7
Reasons:
Adverse event 2
Withdrew consent 4
Other 1

**Completed ARC004
(N=102)**
Total AR101 treatment ~1.5 y

Discontinued 5
Reasons:
Adverse event 1
Withdrew consent 3
Sponsor decision 1

**Completed ARC004
(n=26)**
Total AR101 treatment ~2 y